GlassScriptPhysician profile
Brynn Ledman
NPI 1588343776
$4,294.21
in general payments reported to CMS, 2019-2025
41 companies · $852 in 2025
The $852 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $839 · 2024: $2,603 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,294.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $522.05 | 2023-2025 | |
| Pfizer INC. | $369.71 | 2023-2025 | |
| Novo Nordisk INC | $273.85 | 2025 | Ozempic |
| Jazz Pharmaceuticals INC. | $224.51 | 2023-2024 | |
| Lilly USA, LLC | $224.06 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $196.37 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $168.79 | 2023-2024 | Ultomiris |
| Argenx US, INC. | $164.06 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $162.97 | 2023-2025 | Bimzelx, Nayzilam, Fintepla |
| Sk Life Science, INC. | $146.09 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $144.31 | 2023-2024 | Nuplazid |
| Genentech USA, INC. | $125.67 | 2023-2024 | Ocrevus |
| Neurelis, INC. | $121.92 | 2024 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $109.61 | 2023-2024 | Hyqvia |
| Eisai INC. | $104.40 | 2023-2024 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brynn Ledman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.